Therapeutic advances of new fluoroquinolones

Bibliography

• DOMAGK G: Ein Beitrag zur chemotherapie der bak-teriellen infection. Deutsche Medizinische Wochenschrift (1935) 61:250–253.
   Google Scholar
• ABRAHAM EP: A retrospective view of beta-lactamases. Chemother. (1991) 3(2):67–74.
   Web of Science ®Google Scholar
• LEVY SB: Balancing the drug-resistance equation. Trends Microbiol. (1994) 2 (10) :341–342.
   PubMedGoogle Scholar
• ABRAHAM EP, CHAIN E: An enzyme from bacteria able to destroy penicillin. Nature (1940) 146:837–839.
   Google Scholar
• KELLY JA, DIDEBERG 0, CHARLIER P et al.: On the origin of bacterial resistance to penicillin: comparison of a beta-lactamase and a penicillin target. Science (1986) 231 (4744) :1429–1431.
   Google Scholar
• GOLD HS, MOELLERING RC, Jr.: Antimicrobial-drug re-sistance. New Engl. J. Merl. (1996) 335(19):1445–1453.
   Google Scholar
• COURVALIN P: Transfer of antibiotic resistance genesbetween Gram-positive and Gram-negative bacteria. Antimicrob. Agents Chemother. (1994) 38(7):1447–1451.
   PubMed Web of Science ®Google Scholar
• DOWSON CG, COFFEY TJ, SPRATT BG: Origin and mo-lecular epidemiology of penicillin-binding-protein-mediated resistance to beta-lactam antibiotics. Trends Microbiol. (1994) 2 (10) :361–366.
   PubMedGoogle Scholar
• ANON.: CDC panel develops action plan for drug-resistant streptococci [news]. Am. J. Health. Syst. Pharm. (1996) 53(101113–1116.
   Google Scholar
• DOERN GV, BRUEGGEMANN A, HOLLEY HP, Jr, RAUCHAM: Antimicrobial resistance of Streptococcus pneu-moniae recovered from outpatients in the United States during the winter months of 1994 to 1995: re-sults of a 30-center national surveillance study. Antimi-crob. Agents Chemother. (1996) 40(5):1208–1213.
   PubMed Web of Science ®Google Scholar
• SIMOR AE, LOUIE M, LOW DE: Canadian national surveyof prevalence of antimicrobial resistance among clini-cal isolates of Streptococcus pneumoniae. Canadian Bacterial Surveillance Network. Antimicrob. Agents Che-mother. (1996) 40(9):2190–2193.
   PubMed Web of Science ®Google Scholar
• TOMASZ A: Multiple-antibiotic-resistant pathogenicbacteria. A report on the Rockefeller University Work-shop [see comments]. New Engl. J. Med. (1994) 330(17):1247–1251.
   Google Scholar
• THORNSBERRY C, OGILVIE P, KAHN J, MAURIZ Y: Survei-lance of antimicrobial resistance in S. pneumoniae, H. influenzae, and M catarrhalis in the US during the 1996–97 respiratory season. 35th Annual Meeting Infect. Dis. Soc. Am. San Francisco, California (1997).
   Google Scholar
• BAQUERO F, CANTON R: In vitro activity of sparfloxa-cin in comparison with currently available antimicro-bials against respiratory tract pathogens. J. Antimicrob. Chemother. (1996) 37 (Suppl. A):1–18.
   Google Scholar
• PLOUFFE JF, BREIMAN RF, FACKLAM RR: Bacteremiawith Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group. JAMA (1996) 275 (3) :194–198.
   Google Scholar
• AYLIFFE GA: The progressive intercontinental spreadof methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. (1997) 24 (Suppl. 1):S74–79.
   Google Scholar
• HIRAMATSU K, HANAKI H, INO T et al.: Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility [letter]. J. Antimi-crob. Chemother. (1997) 40(0:135–136.
   PubMed Web of Science ®Google Scholar
• MOELLERING RC, Jr.: Emergence of Enterococcus as asignificant pathogen. Clin. Infect. Dis. (1992) 14 (6):1173–1176.
   PubMed Web of Science ®Google Scholar
• RUBINSTEIN E, KELLER N: Future prospects and thera-peutic potential of streptogramins. Drugs (1996) 51 (Suppl. 1):38–42.
   Google Scholar
• SHLAES DM, BINCZEWSKI B, RICE LB: Emerging antimi-crobial resistance and the immunocompromised host. Clin. Infect. Dis. (1993) 17 (Suppl. 2):S527–536.
   Google Scholar
• THOMSON CJ, AMYES SG: TRC-1: emergence of a clavu- lanic acid-resistant TEM beta-lactamase in a clinical strain. FEMS Microbiol Lett. (1992) 70 (2) :113–117.
   PubMedGoogle Scholar
• RICE LB, WILLEY SH, PAPANICOLAOU GA et al: Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob. Agents Chemother. (1990) 34 (10:2193–2199.
   PubMedGoogle Scholar
• NAUMOVSKI L, QUINN JP, MIYASHIRO D et al.: Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer pa-tients [published erratum appears in Antimicrob. Agents Chemother. 1993 37(2):375]. Antimicrob. Agents Chemother. (1992) 36(9):1991–1996.
   Google Scholar
• MEYER KS, URBAN C, EAGAN JA, BERGER BJ, RAHAL JJ: Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins [see comments]. Ann. Intern. Med. (1993) 119(5):353–358.
   PubMed Web of Science ®Google Scholar
• SANDERS WE, JR., SANDERS CC: Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin. Microbic)]. Rev. (1997) 10 (2) :220–241.
   Google Scholar
• COHEN SP, MCMURRY LM, HOOPER DC, WOLFSON JS, LEVY SB: Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia colise-lected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob. Agents Chemother. (1989) 33(8):1318–1325.
   PubMed Web of Science ®Google Scholar
• HOWE RA, WILSON MP, WALSH TR, MILLAR MR: Suscepti-bility testing of Stenotrophomonas maltophilia to car-bapenems. J. Antimicrob. Chemother. (1997) 40(1):13–17.
   PubMed Web of Science ®Google Scholar
• JACOBS RF: Multiple-drug-resistant tuberculosis. Clin. Infect. Dis. (1994) 19(1):1–8; quiz 9–10.
   Google Scholar
• TILLOTSON G: Tuberculosis - new aspects of chemo-therapy. J. Med. Micro. (1996) 44:16–20.
   Google Scholar
• NATIONAL DATA TRACKING INSTITUTES: Moving An-nual Total. IMS, Plymouth Meeting, PA (June 1997).
   Google Scholar
• SCHENTAG JJ: Understanding and managing microbial resistance in institutional settings. Am. J. Health. Syst. Pharm. (1995) 52(6 Suppl 2):S9–14.
   Google Scholar
• LESCHER GY, FORELICH ED, GRUET MD, BAILEY JH, BRUNDAGE RP: 1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents. J. Med. Pharm. Chem. (1962) 5:1063–1068.
   Web of Science ®Google Scholar
• TILLOTSON GS: Quinolones: structure-activity relation-ships and future predictions. J. Med. Microbiol. (1996) 44 (5):320–324.
   PubMed Web of Science ®Google Scholar
• SMITH JT, LEWIN CS: Chemistry and mechanisms of ac-tion of the quinolone antibacterials. In: The Quinolones. Andriole VT (Eds.), Academic Press, New York (1988)23–83.
   Google Scholar
• KOGA H, ITOH A, MURAYAMA S, SUZUE S, IRIKURA T:Structure-activity relationships of antibacterial 6,7-and 7,8-disubstituted 1-alky1-1,4-dihydro-4-oxoquinoline-3-carboxylic acids. J. Med. Chem. (1980) 23(12):1358–1363.
   PubMed Web of Science ®Google Scholar
• SCHENTAG JJ, DOMAGALA JM: Structure-activity rela-tionships with the quinolone antimbiotics. Res. Clin. Forums (1985) 7:9–15.
   Google Scholar
• DOMAGALA JM: Structure-activity and structure-side-effect relationships for the quinolone antibacterials [published erratum appears in J. Antimicrob. Chemo-ther. 1994 34(5):851]. J. Antimicrob. Chemother. (1994) 33 (4):685–706.
   Google Scholar
• GOOTZ TD, BRIGHTY KE: Fluoroquinolone antibacteri-als: SAR mechanism of action, resistance, and clinical aspects. Med. Res. Rev. (1996) 16(5):433–486.
   PubMed Web of Science ®Google Scholar
• WENTLAND MP: Structure-activity relationships of fluoroquinolones. In: The New Generation of Quinolones. Siporin C, Heifetz CL, Domagala JM (Eds.), Marcel Dekker, Inc., New York (1990):1–45.
   Google Scholar
• BLUM MD, GRAHAM DJ, MCCLOSKEY CA: Temafloxacinsyndrome: review of 95 cases. Clin. Infect. Dis. (1994) 18(6):946–950.
   PubMed Web of Science ®Google Scholar
• LEWIN CS, MORRISSEY I, SMITH JT: The mode of actionof quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environ-ment. Eur. j Clin. Microbiol Infect. Dis. (1991) 10(4)240–248.
   Google Scholar
• BARRY AL, FUCHS PC, BROWN SD: Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA [letter]. Antimicrob. Chemother. (1997) 40(0:139–140.
   Web of Science ®Google Scholar
• FUCHS PC, BARRY AL, BROWN SD: Susceptibility of multi-resistant Streptococcus pneumoniae to cipro-floxacin, ofloxacin and levofloxacin [letter]. J. Antimi-crob. Chemother. (1997) 39(5)671–672.
   Google Scholar
• SEFTON AM, MASKELL JP, RAFAY AM, WHILEY A, WIL-LIAMS JD: The in vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria. J. An-timicrob. Chemother. (1997) 39(Suppl. B):57–62.
   Google Scholar
• DALHOFF A, PETERSEN U, ENDERMANN R: In vitro activ-ity of BAY 12-8039, a new 8-methoxyquinolone. Che-motherapy (1996) 42 (6):410–425.
   Google Scholar
• BREMNER DA, DICKIE AS, SINGH KP: In vitro activity of fleroxacin compared with three other quinolones. J. Antimicrob. Chemother. (1988) 22(Suppl. D):19–23.
   Google Scholar
• BARRY AL, FUCHS PC: Antibacterial activities of gre-pafloxacin, ciprofloxacin, ofloxacin and fleroxacin. J. Chemother. (1997) 9(0:9–16.
   PubMedGoogle Scholar
• ITO T, OTSUKI M, NISHINO T: In vitro antibacterial ac-tivity of Q-35, a new fluoroquinolone. Antimicrob. Agents Chemother. (1992) 36(8):1708–1714.
   PubMed Web of Science ®Google Scholar
• WAKABAYASHI E, MITSUHASHI S: In vitro antibacterialactivity of AM-1155, a novel 6-fluoro-8-methoxy qui-nolone. Antimicrob. Agents Chemother. (1994) 38(3)594–601.
   Google Scholar
• FU KP, LAFREDO SC, FOLENO B etal. In vitro and in vivo antibacterial activities of levofloxacin (1- ofloxacin), an optically active ofloxacin [published erratum ap-pears in Antimicrob. Agents Chemother. 1992 c 36(01797]. Antimicrob. Agents Chemother. (1992) 36 (4):860–866.
   Google Scholar
• FUKUOKA Y, IKEDA Y, YAMASHIRO Y et al.: In vitro and in vivo antibacterial activities of T-3761, a new qui-nolone derivative. Antimicrob. Agents Chemother. (1993) 37 (3):384–392.
   PubMed Web of Science ®Google Scholar
• HOOGKAMP-KORSTANJE JA: In vitro activities of cipro- floxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against Gram-positive and Gram-negative pathogens from res-piratory tract infections [In Process Citation]." Antimi-crob. Chemother. (1997) 40(3)427–431.
   Google Scholar
• BALL P: Bacterial resistance to fluoroquinolones: les- sons to be learned. Infection (1994) 22 (Suppl. 2):S140–147.
   Google Scholar
• NIEDERMAN M, TRAUB S, ELLISON WT, HOPKINS DW, THE TROVAN PNEUMONIA STUDY GROUP: A double blind, randomized, multicenter, global study in hospi-talized community acquired pneumonia comparing trovafloxacin with ceftriaxone and erythromycin. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada (1997)377. Abstr. LM–72.
   Google Scholar
• SULLIVAN J, GEZON J, WILLIAMS HOPKINS D, THE TRO- VAN COMMUNITY PNEUMONIA STUDY GROUP: A dou-ble blind, randomized, multicenter study in ambulatory community acquired pneumonia compar-ing trovafloxacin with clarithromycin. 37th Intersci-ence Conference on Antimicrobial Agents and Chemotherapy Toronto, Ontario, Canada (1997)377. Abstr. LM–73.
   Google Scholar
• GRAHAM DR, KLEIN T, TORRES A, NIEDERMANN M, THE TROVAN NOSOCOMIAL PNEUMONIA STUDY GROUP: A double blind, randomized, multicenter study of noso-comial pneumonia comparing trovafloxacin with ciprofloxacin+-clindamycin/metronidazole. 37th In-terscience Conference on Antimicrobial Agents and Chemo-therapy Toronto, Ontario, Canada (1997)378. Abstr. LM–74.
   Google Scholar
• SCHENTAG JJ, NIX DE, FORREST A, ADELMAN MH AUIC - the universal parameter within the constraint of a rea-sonable dosing interval [editorial; comment]. Ann. Pharmacother. (1996) 30(9) 1029–1031
   PubMed Web of Science ®Google Scholar
• FORREST A, NIX DE, BALLOW CH et al.: Pharmacody-namics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. (1993) 37 (5):1073–1081.
   PubMed Web of Science ®Google Scholar
• WISER, HONEYBOURNE D: A review of the penetrationof sparfloxacin into the lower respiratory tract and si-nuses. J. Antimicrob. Chemother. (1996) 37 (Suppl. 457–63.
   Google Scholar
• MEYERS B: Antimicrobial Therapy Guide. AntimicrobialPrescribing, Inc., Penn, USA (1997):173.
   Google Scholar
• MONTAY G: Pharmacokinetics of sparfloxacin inhealthy volunteers and patients: a review. J. Antimi-crob. Chemother. (1996) 37 (Suppl. A):27–39.
   Google Scholar
• BERGAN T: Pharmocokinetics of fluorinated qui-nolones. In: The Quinolones. Andriole VT (Ed.), Academic Press, New York (1988):119–145.
   Google Scholar
• MCDONALD PJ, PRUUL H: Quinolones and the immune system. In: The New Generation of Quinolones. Siporin C, Heifetz CL, Domagala JM (Eds.), Marcel Dekker, Inc., New York (1990):107–123.
   Google Scholar
• ANZUETO A, NIEDERMAN MS, HAVERSTOCK DC, TILLOT-SON GS: Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: interim analysis. Clin. Therapeut. (1997) 19(5):975–988.
   PubMed Web of Science ®Google Scholar
• BENSCH GW, KLAUSTERMEYER WB, MCCARTY J, SCHWORER PB, TAGLIETTI MA: Efficacy and safety of once-daily ceftibuten versus twice-daily ciprofloxacin in the treatment of acute exacerbation of chronic bronchitis. Infect. Dis. Clin. Pract. (1995) 4\(Suppl. 2):S80–S87.
   Google Scholar
• FINK MP, SNYDMAN DR, NIEDERMAN MS et al.: Treat-ment of severe pneumonia in hospitalized patients: re-sults of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group [see comments]. Antimicrob. Agents Chemother. (1994) 38(3):547–557.
   PubMed Web of Science ®Google Scholar
• JOHNSON RH, LEVINE S, TRAUB SL et al.: Sequential in-travenous/oral ciprofloxacin compared to parenteral ceftriaxone in the treatment of hospitalized patients with community-acquired pneumonia. Infect. Dis. Clin. Pract. (1996) 5(4):265–272.
   Web of Science ®Google Scholar
• LEE BL, PADULA AM, KIMBROUGH RC et al.: Infectious complications with respiratory pathogens despite ciprofloxacin therapy [letter]. New Engl. J. Med. (1991) 325 (7):520–521.
   PubMed Web of Science ®Google Scholar
• BALL AP, TILLOTSON GS: Lower respiratory tract infec-tion therapy - the role of ciprofloxacin. J. Int. Med. Res. (1995) 23(5):315–327.
   PubMed Web of Science ®Google Scholar
• PORTIER H, MAY T, PROUST A, THE FRENCH STUDY GROUP: Comparative efficacy of sparfloxacin in com-parison with amoxycillin plus ofloxacin in the treat-ment of community-acquired pneumonia. J. Antimicrob. Chemother. (1996) 37 (Suppl. 483–91.
   Google Scholar
• DONOWITZ GR, BRANDON ML, SALISBURY JP et al.: Spar-floxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study. Clin. Therapeut. (1997) 19(5):936–953.
   PubMed Web of Science ®Google Scholar
• LODE H, GARAU J, GRASSI C et al.: Treatment of community-acquired pneumonia: a randomized com-parison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin [see comments]. Eur. Respir. J. (1995) 8(12):1999–2007.
   PubMed Web of Science ®Google Scholar
• ORTQVIST A, VALTONEN M, CARS 0 et al.: Oral empiric treatment of community-acquired pneumonia. A mul-ticenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group. Chest (1996) 110 (6) :1499–1506.
   Google Scholar
• GEHANNO P, BERCHE P, GROUP. TSS: Sparfloxacin ver-sus cefuroxime axetil in the treatment of acute puru-lent sinusitis. J. Antimicrob. Chemother. (1996) 37 (Suppl. 4105–114.
   Google Scholar
• ALLEGRA L, KONIETZKO N, LEOPHONTE P et al.: Com-parative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstruc-tive pulmonary disease: a double-blind, randomised, parallel, multicenter study. J. Antimicrob. Chemother. (1996) 37 (Suppl. A):93–104.
   Google Scholar
• DEABATE CA, THE SPAR MULTICENTER ABECB STUDYGROUP: Treatment of acute bacterial exacerbations of chronic bronchitis with sparfloxacin and ofloxacin. 36th Intel-science Conference on Antimicrobial Agents and Chemotherapy. New Orleans, Louisiana, USA (1996).
   Google Scholar
• LIPSKY BA, THE SPAR MULTICENTER SSSI STUDY GROUP:Treatment of community-acquired complicated skin and skin structure infections with sparfloxacin and ciprofloxacin. 36th Intel-science Conference on Antimicro-bial Agents and Chemotherapy. New Orleans, Louisiana, USA (1996).
   Google Scholar
• FILE TM, Jr., SEGRETI J, DUNBAR L et al.: A multicenter,randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftri-axone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. (1997) 41(9):1965–1972.
   Google Scholar
• CARBON C, THE INTERNATIONAL STUDY GROUP: Com-parative study of levofloxacin and co-amoxiclav in the treatment of community-acquired pneumonia in adults. 37th Intel-science Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada (1997):377. Abstr. LM–70.
   Google Scholar
• HABIB MP, GENTRY LO, RODRIGUEZ-GOMEZ G, MOR-OWITZ W, WILLIAMS R: A multicenter randomized study comparing the efficacy and safety of oral levo-floxacin versus cefaclor in the treatment of acute bac-terial exacerbations of chronic bronchitis. 36th Intel-science Conference on Antimicrobial Agents and Che-motherapy. New Orleans, Louisiana, USA (1996).
   Google Scholar
• SHAH PM, THE INTERNATIONAL STUDY GROUP: Levo-floxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis. 37th Intel-sci-ence Conference on Antimicrobial Agents and Chemother-apy. Toronto, Ontario, Canada (1997):371. Abstr. LM–38.
   Google Scholar
• GENTRY LO: Treatment of skin and soft tissue infec-tions with quinolone antimicrobial agents. In: Qui-nolone Antimicrobial Agents. Hooper DC, Wolfson JS (Eds.), American Society for Microbiology, Washington DC, USA (1993):413–423.
   Google Scholar
• NORRBY SR: Treatment of urinary tract infections with quinolone antimicrobial agents. In: Quinolone Antimi-crobial Agents. Hooper DC, Wolfson JS (Eds.), American So-ciety for Microbiology, Washington DC, USA (1993):273–285.
   Google Scholar
• LEWD, WALDVOGEL F: Use of quinolones for treatment of osteomyelitis and septic arthritis. In: Quinolone Anti-microbial Agents. Hooper DC and Woffson JS (Eds), American Society for Microbiology, Washington DC, USA (1993) :371–381.
   Google Scholar
• PATEL T, DESAI R, DUFF J et al.: Comparison of gre-pafloxacin with clarithromycin in the treatment of community-acquired pneumonia. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Ontario, Canada (1997)377. Abstr. LM–69.
   Google Scholar
• KOBAYASHI H: A multicenter, double-blind compara-tive study of grepfloxacin versus ofloxacin in the treatment of pneumonia. 36th Intel-science Conference on Antimicrobial Agents and Chemotherapy. New Orleans, Louisiana, USA (1996).
   Google Scholar
• KOBAYASHI H: A multicenter, double-blind compara-tive study of grepfloxacin versus ofloxacin in the treatment of chronic respiratory tract infection. 36th Intel-science Conference on Antimicrobial Agents and Che-motherapy New Orleans, Louisiana, USA (1996).
   Google Scholar
• LANGAN C, CRANFIELD R, BREISCH S, PETIT R: The effi-cacy and safety of grepafloxacin 400 mg qd or 600 mg qd in the treatment of acute bacterial exacerbations of chronic bronchitis: comparison with amoxycillin 500 mg tid. 8th European Congress of Clinical Microbiology and Infectious Diseases. Lausanne, Switzerland (1997).
   Google Scholar
• CHODOSH S, LAKSHMINARAYAN S, SWARZ H, BREISCH S: The efficacy and safety of grepafloxacin 400 mg qd or 600 mg qd in the treatment of acute bacterial exacer-bations of chronic bronchitis: comparison with cipro-floxacin 500 mg bid. 20th International Congress of Chemotherapy. Sydney, Australia (1997).
   Google Scholar
• WAGSTAFF AJ, BALFOUR JA: Grepafloxacin. Drugs (1997) 53(5):817–824; discussion 825–7.
   Google Scholar
• MANDELL L, WILLIAMS HOPKINS D, HOPKINS S: Efficacy of trovafloxacin in patients with community acquired pneumonia due to penicillin susceptible and resistant S. pneumoniae. 37th Intel-science Conference on Antimi-crobial Agents and Chemotherapy. Toronto, Ontario, Can-ada (1997):377. Abstr. LM–71.
   Google Scholar
• ALDRIDGE KE, ASHCRAFT DS: Comparison of the in vi-tro activities of Bay 12–8039, a new quinolone, and other antimicrobials against clinically important an-aerobes. Antimicrob. Agents Chemother. (1997) 41(3)709–711.
   Google Scholar
• STASS HH, DEITRICH H, SACHSE E: Influence of a four times dosing of 500 mg probenicid on kinetics of Bay 12–8039 after administration of a single 400 mg dose in healthy male volunteers. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada (1997):172. Abstr. F–154.
   Google Scholar
• WOODCOCK JM, ANDREWS JM, BOSWELL FJ, BRENWALD NP, WISE R: In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob. Agents Chemother. (1997) 41 (1):101–106.
   PubMed Web of Science ®Google Scholar
• BALL P: Long-term use of quinolones and their safety. Rev. Infect. Dis. (1989) 11 (Suppl. 5):51365–70.
   Google Scholar
• KENNEDY N, FOX R, UISO L, NGOWI Fl, GILLESPIE SH: Safety profile of ciprofloxacin during long-term ther-apy for pulmonary tuberculosis. J. Antimicrob. Chemo-ther. (1993) 32(6): 897–902.
   PubMed Web of Science ®Google Scholar
• BALL P, TILLOTSON G: Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug. Saf (1995) 13(6): 343–58.
   Google Scholar
• LIETMAN PS: Fluoroquinolone toxicities. An update. Drugs (1995) 49 (Suppl. 2):159–163.
   Google Scholar
• ORTHO-MCNEIL PHARMACEUTICAL CORPORATION: Levoquin Package Insert, USA (1997).
   Google Scholar
• RHONE-POULENC RORER: Sparfloxacin Package Insert, USA (1997).
   Google Scholar
• JAILLON P, MORGANROTH J, BRUMPT I, TALBOT G: Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. J. Antimicrob. Chemother. (1996) 37 (Suppl. A):161–167.
   Google Scholar
• GLAXO WELLCOME: Grepafloxacin Package Insert, USA (1997).
   Google Scholar
• DOERN GV, BRUEGGEMANN AB, PIERCE G, HOLLEY HP, Jr., RAUCH A: Antibiotic resistance among clinical iso-lates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob. Agents Chemother. (1997) 41(2)292–297.
   Google Scholar
• HOOPER DC, WOLFSON JS: Quinolone Antimicrobial Agents. American Society for Microbiology, Washington, DC, USA (1993):1–535.
   Google Scholar
• ARKY R: Physicians' Desk Reference. Medical Economics Company, Montvale, NJ (1997):402–2986.
   Google Scholar
• PFIZER, INC.: Trovafloxacin Package Insert, USA (1998).
   Google Scholar
• BAUERNFEIND A: Comparative in vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, spar-floxacin, tosufloxacin, CI-960 and CI-990 [see com-ments]. J. Antimicrob. Chemother. (1993) 31(4)505–522.
   Google Scholar
• BIEDENBACH DJ, JONES RN: In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spec-trum of activity against Gram-positive aerobic organ-isms and anaerobes. Antimicrob. Agents Chemother. (1995) 39(7):1636–1642.
   PubMed Web of Science ®Google Scholar
• COHEN MA, HUBAND MD, GAGE JW et al: In vitro activ-ity of clinafloxacin, trovafloxacin, and ciprofloxacin [In Process Citation]. J. Antimicrob. Chemother. (1997) 40 (2) :205–11.
   PubMed Web of Science ®Google Scholar
• FELMINGHAM D, ROBBINS MJ, INGLEY K et al.: In vitro activity of trovafloxacin: a new fluoroquinolone, against recent clinical isolates. J. Antimicrob. Chemother. (1997) 39(Suppl. B):43–49.
   Google Scholar
• GOHARA Y, ARAI S, AKASHI A et al: In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae. Antimicrob. Agents Chemo-ther. (1993) 37(9):1826–1830.
   PubMed Web of Science ®Google Scholar
• GOODING BB, ERWIN ME, BARRETT MS, JOHNSON DM, JONES RN: Antimicrobial activities of two investiga-tional fluoroquinolones (CI- 960 and E4695) against over 100 Legionella spp. isolates. Antimicrob. Agents Chemother. (1992) 36(9):2049–2050.
   PubMed Web of Science ®Google Scholar
• ISHIDA K, KAKU M, IRIFUNE K et al.: In vitro and in vivo activity of a new quinolone AM-1155 against Myco-plasma pneumoniae. J. Antimicrob. Chemother. (1994) 34 (6):875–883.
   PubMed Web of Science ®Google Scholar
• IWASAKI H, MIYAZAKI S, TSUJI A, YAMAGUCHI K, GOTO S: In vitro and in vivo antibacterial activities of Q-35, a novel fluoroquinolone. Chemotherapy (1995) 41 (2):100–112.
   PubMed Web of Science ®Google Scholar
• MIYASHITA N, NIKI Y, KISHIMOTO T, NAKAJIMA M, MAT-SUSHIMA T: In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimi-crob. Agents Chemother. (1997) 41(6):1331–1334.
   PubMed Web of Science ®Google Scholar
• SPANGLER SK, JACOBS MR, APPELBAUM PC: Activity of CP 99,219 compared with those of ciprofloxacin, gre-pafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin- tazobactam against 489 anaerobes. Antimicrob. Agents Chemother. (1994) 38(102471–2476.
   Google Scholar
• VAISANEN ML, MATTO J, SALMINEN K, JOUSIMIES-SOMER H: In vitro activity of trovafloxacin against aerobic and anaerobic bacteria. 37th Intel-science Conference on Anti-microbial Agents and Chemotherapy (1997) :114. Abstr. El.
   Google Scholar
• EDELSTEIN PH, EDELSTEIN MA, WEIDENFELD J, DORR MB: In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L pneu-mophila pneumonia. Antimicrob. Agents Chemother. (1990) 34(10:2122–2127.
   PubMedGoogle Scholar
• KLUGMAN KP, GOOTZ TD: In vitro and in vivo activity of trovafloxacin against Streptococcus pneumoniae. J. Antimicrob. Chemother. (1997) 39 (Suppl. B):51–55.
   Google Scholar
• EDELSTEIN PH, EDELSTEIN MA, REN J, POLZER R, GLADUE RP: Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellu-lar accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemo-ther. (1996) 40(2):314–319.
   PubMed Web of Science ®Google Scholar
• ROLSTON KV, HO DH, LEBLANC B, STREETER H, DVO-RAK T: In vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer. J. Antimi-crob. Chemother. (1997) 39(Suppl. B):15–22.
   Google Scholar
• CHILD J, ANDREWS J, BOSWELL F, BRENWALD N, WISE R: The in vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroqui-nolone agents. J. Antimicrob. Chemother. (1995) 35 (6):869–876.
   PubMed Web of Science ®Google Scholar
• NEU HC, CHIN NX: In vitro activity of the new fluoro-quinolone CP-99,219. Antimicrob. Agents Chemother. (1994) 38(10:2615–2622.
   PubMedGoogle Scholar
• WADWORTH AN, GOA KL: Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use [published erratum appears in Drugs 1992 44(1):8]. Drugs (1991) 42(6):1018–1060.
   Google Scholar
• BAUERNFEIND A: Comparison of the antibacterial ac-tivities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. (1997) 40(5):639–651.
   PubMed Web of Science ®Google Scholar
• DAVIS R, MARKHAM A, BALFOUR JA: Ciprofloxacin. An updated review of its pharmacology, therapeutic effi-cacy and tolerability. Drugs (1996) 51(6):1019–1074.
   Google Scholar
• BRON NJ, DORR MB, MANT TG, WEBB CL, VASSOS AB: The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects. J. Antimicrob. Chemother. (1996) 38(6):1023–1029.
   PubMed Web of Science ®Google Scholar
• NAKASHIMA M, UEMATSU T, KOSUGE K etal.: Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob. Agents Chemother. (1995) 39(12):2635–2640.
   Google Scholar
• CHILD J, ANDREWS JM, WISE R: Pharmacokinetics and tissue penetration of the new fluoroquinolone gre-pafloxacin. Antimicrob. Agents Chemother. (1995) 39 (2):513–515.
   PubMed Web of Science ®Google Scholar
• DAVIS R, BRYSON HM: Levofloxacin. A review of its an-tibacterial activity, pharmacokinetics and therapeutic efficacy [published erratum appears in Drugs 1994 48(1):132]. Drugs (1994) 47(4):677–700.
   Google Scholar
• GOA KL, BRYSON HM, MARKHAM A: Sparfloxacin. A re-view of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs (1997) 53(4)700–725.
   Google Scholar
• HARIA M, LAMB HM: Trovafloxacin. Drugs (1997) 54(3):435–445; discussion 446.
   Google Scholar
• ANDREWS JM, HONEYBOURNE D, BRENWALD NP et al: Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and se-rum after administration of single or multiple oral doses to patients undergoing fibre-optic broncho-scopy. J. Antimicrob. Chemother. (1997) 39(6)797–802.
   Google Scholar
• COOK PJ, ANDREWS JM, WISE R, HONEYBOURNE D, MOUDGIL H: Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung com-partments. J. Antimicrob. Chemother. (1995) 35(2)317–326.
   Google Scholar
• ANDREWS JM, HONEYBOURNE D, JEVONS G et al.: Con-centrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergo-ing fibre-optic bronchoscopy [In Process Citation]. J. Antimicrob. Chemother. (1997) 40(4):573–577.
   PubMed Web of Science ®Google Scholar
• DECRE D, BERGOGNE-BEREZIN E: Pharmacokinetics of quinolones with special reference to the respiratory tree. J. Antimicrob. Chemother. (1993) 31(3):331–343.
   PubMed Web of Science ®Google Scholar
• WISE R: Comparative penetration of selected fluoro-quinolones into respiratory tract fluids and tissues. Am. J Med. (1991) 91 (6A):67S-70S.138. HEYD A, ECHOLS R, SHAN M: Oral ciprofloxacin versus cefuroxime axetil in the treatment of acute siunusitis. 35th Intel-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, California, USA (1995).
   Google Scholar
• ADELGLASS J, DEABATE CA, MCELVAINE P, FOWLER CL: A comparison of levofloxacin and amoxicillin/clavula-nate for the treatment of acute bacterial sinusitis in adults. Clin. Infect. Dis. (1996) 23 (Abstract 290):913.
   Google Scholar
• WINSTON DJ, BLUMER J, BERVERIDGE R et al.: Random-ized, multicenter, double-blind trial of clinafloxacin versus imipenem for empiric therapy of febrile granu-locytopenic patients. 20th International Congress of Che-motherapy. Sydney, Australia (1997).
   Google Scholar